Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping cancer.

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report.

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to an experimental, personalized cancer vaccine, researchers reported Feb. 5.

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to long-lasting T cell expansion and no disease recurrence after 40 months.

The vaccine acts like a "wanted poster" unmasking cancer cells that are adept at hiding in the body, only to resurface later. The hope is that the vaccine primes the immune system to seek out and destroy any remaining traces of cancer, improving the chances of being cancer-free in years to come.

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the vaccine candidate appeared to be safe and produced a clear immune response in all nine patients at high risk for recurrences of their cancer.

A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer three years after the pioneering treatment.

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated robust immune response, according to findings of a new study led by HMS researchers at Dana-Farber Cancer Institute.

The fusion of mRNA technology with AI has laid the foundation for ushering in a new era of cancer care. However, conducting large-scale clinical trials for potential vaccine candidates remains a significant challenge,